MORE NEWS

APLA 2022 Registrations are Open

July 13, 2022

APLA, the Latin American Petrochemical and Chemical Association organizes the 42nd Latin American Petrochemical Annual Meeting, to be held November 12-15, 2022 at the Grand Fiesta Americana Coral Beach Cancun, Mexico.

The meeting brings together every year the leaders and decision-makers of the petrochemical and chemical industry in the region and in its 42nd edition, it will have a 100% face-to-face proposal, being the right place to conduct negotiations and presentations, develop and consolidate business, exchange knowledge and generate valuable contacts.

During this meeting, debates on sustainability, challenges in energy supply and logistics in the sector will play a leading role.

The program includes seminars, lectures, social and networking spaces.

You can learn more here.

INTERVIEWS MORE INTERVIEWS

Dan Vujcic

CEO, SOLGOLD

"The first US$100 million of the Franco - Osisko stream is designated for pre-development, while the larger chunk of US$650 million will finance approximately 42% of our CapEx requirement."

"Our exploration program for the next four years represents a comprehensive approach to hydrocarbon discovery across Angola's diverse geological provinces."

MINISTER OF NATURAL RESOURCES, GOVERNMENT OF NEW BRUNSWICK

"By targeting committed investors and maintaining strong regulatory and Indigenous relations, the province hopes to accelerate responsible mineral development and establish itself as a serious, results-oriented jurisdiction."

Mining

Canada

Peter Hagen

CEO, ALGOA CABINDA FABRICATION SERVICES

"There is still a lot of work in Cabinda, especially with ageing fields that require ongoing maintenance and the potential for new developments."

Oil & Gas

South Africa

Energy

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

MORE PREVIOUSLY PUBLISHED